Different sites of extranodal involvement may affect the survival of patients with relapsed or refractory non-Hodgkin lymphoma after chimeric antigen receptor T cell therapy

{{article.zuoZheEn}}

PDF(344 KB)
PDF(344 KB)
Front. Med. ›› 2020, Vol. 14 ›› Issue (6) : 786-791. DOI: 10.1007/s11684-020-0751-3
RESEARCH ARTICLE

Different sites of extranodal involvement may affect the survival of patients with relapsed or refractory non-Hodgkin lymphoma after chimeric antigen receptor T cell therapy

  • {{article.zuoZheEn}}
Author information +
History +

Highlights

{{article.highlightEn}}

Abstract

{{article.abstractEn}}

Author summary

{{article.authorSummayEn}}

Keywords

Cite this article

EndNote

Ris (Procite)

Bibtex

Download citation ▾
{{article.zuoZheEn_L}}. {{article.titleEn}}. Front. Med., 2020, 14(6): 786‒791 https://doi.org/10.1007/s11684-020-0751-3

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

RIGHTS & PERMISSIONS

{{article.copyright.year}} {{article.copyright.holder}}
PDF(344 KB)

Accesses

Citations

Detail
Sections
Recommended

/

〈 〉